Recombinant human interleukin-1 receptor antagonist reduces acute lethal toxicity and protects hematopoiesis from chemotoxicity in vivo

Biomedicine and Pharmacotherapy

Volumn 67, Issue 2, 2013, Pages 108-115

  Qian, Lan ^a   Xiang, Di ^a   Zhang, Jing ^a   Zhu, Shunying ^a   Gao, Jin ^a   Wang, Xia ^a   Gao, Jing ^a   Zhang, Yang ^a   Shen, Jiaqing ^b   Yu, Yan ^a   Han, Wei ^a   Wu, Mingyuan ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

Chemotherapy induced myelosuppression; Hematopoiesis; Inteuleukin 1 receptor antagonist

Indexed keywords

CYCLOPHOSPHAMIDE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ACUTE TOXICITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DAMAGE; CELL PROTECTION; CONTROLLED STUDY; DISEASE SEVERITY; EXPERIMENTAL DOG; HEMATOPOIESIS; HEMATOPOIETIC CELL; IN VIVO STUDY; LETHALITY; MORBIDITY; MOUSE; NEUTROPENIA; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ALDEHYDE DEHYDROGENASE; ANIMALS; ANTINEOPLASTIC AGENTS; BONE MARROW CELLS; CYCLOPHOSPHAMIDE; DOGS; HEMATOPOIETIC STEM CELLS; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; MICE; MICE, INBRED BALB C; NEUTROPENIA; RECEPTORS, INTERLEUKIN-1; RECOMBINANT PROTEINS;

EID: 84875376192     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2012.11.002     Document Type: Article

References (37)

1. Lieschke G.J., Burgess A.W. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (1). N Engl J Med 1992, 327:28-35.
2. Lieschke G.J., Burgess A.W. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (2). N Engl J Med 1992, 327:99-106.
3. Kuter D.J., Begley C.G. Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood 2002, 100:3457-3469.
4. van Os R., Robinson S., Sheridan T., Mislow J.M., Dawes D., Mauch P.M. Granulocyte colony-stimulating factor enhances bone marrow stem cell damage caused by repeated administration of cytotoxic agents. Blood 1998, 92:1950-1956.
5. Voloshin T., Gingis-Velitski S., Bril R., Benayoun L., Munster M., Milsom C., et al. G-CSF supplementation with chemotherapy can promote revascularization and subsequent tumor regrowth: prevention by a CXCR4 antagonist. Blood 2011, 118:3426-3435.
6. Hirbe A.C., Uluckan O., Morgan E.A., Eagleton M.C., Prior J.L., Piwnica-Worms D., et al. Granulocyte colony-stimulating factor enhances bone tumor growth in mice in an osteoclast-dependent manner. Blood 2007, 109:3424-3431.
7. Moore M.A., Warren D.J. Synergy of interleukin 1 and granulocyte colony-stimulating factor: in vivo stimulation of stem-cell recovery and hematopoietic regeneration following 5-fluorouracil treatment of mice. Proc Natl Acad Sci U S A 1987, 84:7134-7138.
8. Crown J., Jakubowski A., Kemeny N., Gordon M., Gasparetto C., Wong G., et al. A phase I trial of recombinant human interleukin-1 beta alone and in combination with myelosuppressive doses of 5-fluorouracil in patients with gastrointestinal cancer. Blood 1991, 78:1420-1427.
9. Damia G., Komschlies K.L., Futami H., Back T., Gruys M.E., Longo D.L., et al. Prevention of acute chemotherapy-induced death in mice by recombinant human interleukin 1: protection from hematological and nonhematological toxicities. Cancer Res 1992, 52:4082-4089.
10. Smith J.W., Longo D.L., Alvord W.G., Janik J.E., Sharfman W.H., Gause B.L., et al. The effects of treatment with interleukin-1 alpha on platelet recovery after high-dose carboplatin. N Engl J Med 1993, 328:756-761.
11. Smith J.W., Urba W.J., Curti B.D., Elwood L.J., Steis R.G., Janik J.E., et al. The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignancies. J Clin Oncol 1992, 10:1141-1152.
12. Hannum C.H., Wilcox C.J., Arend W.P., Joslin F.G., Dripps D.J., Heimdal P.L., et al. Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature 1990, 343:336-340.
13. Kirisawa R., Fukuda T., Yamanaka H., Hagiwara K., Goto M., Obata Y., et al. Enzymatic amplification and expression of bovine interleukin-1 receptor antagonist cDNA. Vet Immunol Immunopathol 1998, 62:197-208.
14. Granowitz E.V., Porat R., Mier J.W., Pribble J.P., Stiles D.M., Bloedow D.C., et al. Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans. Cytokine 1992, 4:353-360.
15. Fleischmann R.M., Tesser J., Schiff M.H., Schechtman J., Burmester G.R., Bennett R., et al. Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann Rheum Dis 2006, 65:1006-1012.
16. Zhang J., Xiang D., Zhu S., Mao W., Lu H., Wu M., et al. Interleukin 1 receptor antagonist inhibits normal hematopoiesis and reduces lethality and bone marrow toxicity of 5-fluouracil in mouse. Biomed Pharmacother 2009, 63:501-508.
17. Su D.M., Manley N.R. Stage-specific changes in fetal thymocyte proliferation during the CD4-8- to CD4+8+ transition in wild type, Rag1-/-, and Hoxa3,Pax1 mutant mice. BMC Immunol 2002, 3:12.
18. Kastan M.B., Schlaffer E., Russo J.E., Colvin O.M., Civin C.I., Hilton J. Direct demonstration of elevated aldehyde dehydrogenase in human hematopoietic progenitor cells. Blood 1990, 75:1947-1950.
19. Jones R.J., Barber J.P., Vala M.S., Collector M.I., Kaufmann S.H., Ludeman S.M., et al. Assessment of aldehyde dehydrogenase in viable cells. Blood 1995, 85:2742-2746.
20. Storms R.W., Trujillo A.P., Springer J.B., Shah L., Colvin O.M., Ludeman S.M., et al. Isolation of primitive human hematopoietic progenitors on the basis of aldehyde dehydrogenase activity. Proc Natl Acad Sci U S A 1999, 96:9118-9123.
21. Povsic T.J., Zavodni K.L., Kelly F.L., Zhu S., Goldschmidt-Clermont P.J., Dong C., et al. Circulating progenitor cells can be reliably identified on the basis of aldehyde dehydrogenase activity. J Am Coll Cardiol 2007, 50:2243-2248.
22. Hilton J. Role of aldehyde dehydrogenase in cyclophosphamide-resistant L1210 leukemia. Cancer Res 1984, 44:5156-5160.
23. Moreb J., Zucali J.R., Zhang Y., Colvin M.O., Gross M.A. Role of aldehyde dehydrogenase in the protection of hematopoietic progenitor cells from 4-hydroperoxycyclophosphamide by interleukin 1 beta and tumor necrosis factor. Cancer Res 1992, 52:1770-1774.
24. DeVita V.T., Chu E. A history of cancer chemotherapy. Cancer Res 2008, 68:8643-8653.
25. Wright D.E., Cheshier S.H., Wagers A.J., Randall T.D., Christensen J.L., Weissman I.L. Cyclophosphamide/granulocyte colony-stimulating factor causes selective mobilization of bone marrow hematopoietic stem cells into the blood after M phase of the cell cycle. Blood 2001, 97:2278-2285.
26. Arend W.P. The balance between IL-1 and IL-1Ra in disease. Cytokine Growth Factor Rev 2002, 13:323-340.
27. Fischer E., Van Zee K.J., Marano M.A., Rock C.S., Kenney J.S., Poutsiaka D.D., et al. Interleukin-1 receptor antagonist circulates in experimental inflammation and in human disease. Blood 1992, 79:2196-2200.
28. Wu Z., Han X., Qin S., Zheng Q., Wang Z., Xiang D., et al. Interleukin 1 receptor antagonist reduces lethality and intestinal toxicity of 5-fluorouracil in a mouse mucositis model. Biomed Pharmacother 2010, 64:589-593.
29. Zhu J., Zhang J., Zhang L., Du R., Xiang D., Wu M., et al. Interleukin-1 signaling mediates acute doxorubicin-induced cardiotoxicity. Biomed Pharmacother 2011, 65:481-485.
30. Shen J., Gao J., Zhang J., Xiang D., Wang X., Qian L., et al. Recombinant human interleukin-1 receptor antagonist (rhIL-1Ra) attenuates caerulein-induced chronic pancreatitis in mice. Biomed Pharmacother 2012, 66:83-88.
31. Dong Q., Barsky D., Colvin M.E., Melius C.F., Ludeman S.M., Moravek J.F., et al. A structural basis for a phosphoramide mustard-induced DNA interstrand cross-link at 5'-d(GAC). Proc Natl Acad Sci U S A 1995, 92:12170-12174.
32. Rodriguez-Antona C., Ingelman-Sundberg M. Cytochrome P450 pharmacogenetics and cancer. Oncogene 2006, 25:1679-1691.
33. McKinstry W.J., Li C.L., Rasko J.E., Nicola N.A., Johnson G.R., Metcalf D. Cytokine receptor expression on hematopoietic stem and progenitor cells. Blood 1997, 89:65-71.
34. Ueda Y., Cain D.W., Kuraoka M., Kondo M., Kelsoe G. IL-1R type I-dependent hemopoietic stem cell proliferation is necessary for inflammatory granulopoiesis and reactive neutrophilia. J Immunol 2009, 182:6477-6484.
35. Neta R., Sztein M.B., Oppenheim J.J., Gillis S., Douches S.D. The in vivo effects of interleukin 1. I. Bone marrow cells are induced to cycle after administration of interleukin 1. J Immunol 1987, 139:1861-1866.
36. Dinarello C.A. Biologic basis for interleukin-1 in disease. Blood 1996, 87:2095-2147.
37. Watari K., Mayani H., Lee F., Dragowska W., Lansdorp P.M., Schrader J.W. Production of interleukin 1beta by human hematopoietic progenitor cells. J Clin Invest 1996, 97:1666-1674.